Press release
Respiratory Syncytial Virus Pipeline, Clinical Trials, and Emerging Drugs (2023) | Companies- GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, and others
Respiratory Syncytial Virus Infection Pipeline
In the Respiratory Syncytial Virus Infection Pipeline Report, detailed description of the drug is given which includes the mechanism of action of the drug, Respiratory Syncytial Virus Infection clinical trials studies, Respiratory Syncytial Virus Infection NDA approvals (if any), and product development activities comprising the technology, Respiratory Syncytial Virus (RSV) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
To explore more information on the latest breakthroughs in the Respiratory Syncytial Virus Infection Pipeline treatment landscape of the report, click here @ Respiratory Syncytial Virus Infection Pipeline Outlook- https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Respiratory Syncytial Virus Infection Pipeline Report
• DelveInsight's Respiratory Syncytial Virus Infection Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies.
• The leading Respiratory Syncytial Virus Infection Companies are working in the market include GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others
• Promising Respiratory Syncytial Virus Infection Pipeline Therapies in the various stages of development include CS1001, avelumab, Isatuximab, Cemiplimab, Daratumumab, Velcade, CHOP and alemtuzumab, Busulfan, Fludarabine, YY-20394, and others
• On May, 2023, Athenex Inc has announced a drug named KUR-502 in the market of phase 1. This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).
Respiratory Syncytial Virus Infection Overview
Respiratory syncytial virus (RSV) is a very common cause of respiratory tract infection, particularly in children. Nearly all children have been infected by age 4 years, many in the first year of life. Infection does not provide complete immunity, so reinfection is common, although usually less serious. Outbreaks typically occur in winter and early spring.
For further information, refer to the detailed Respiratory Syncytial Virus Infection Unmet Needs, Respiratory Syncytial Virus Infection Market Drivers, and Market Barriers, click here for Respiratory Syncytial Virus Infection Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Respiratory Syncytial Virus Infection Emerging Drugs Profile
• GSK3844766A: GlaxoSmithKline
• Nirsevimab (MEDI-8897): MedImmune
• Sisunatovir: ReViral
Respiratory Syncytial Virus Infection Pipeline Therapeutics Assessment
There are approx. 50+ Respiratory Syncytial Virus Infection companies which are developing the therapies for Respiratory Syncytial Virus (RSV). The Respiratory Syncytial Virus Infection companies which have their Respiratory Syncytial Virus (RSV) drug candidates in the most advanced stage, i.e. phase III include, GlaxoSmithKline.
Request a sample and discover the recent advances in Respiratory Syncytial Virus Infection Ongoing Clinical Trial Analysis and Medications, click here @ Respiratory Syncytial Virus Infection Treatment Landscape- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Respiratory Syncytial Virus Infection Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Respiratory Syncytial Virus Infection Therapeutics Market include-
GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others.
Dive deep into rich insights for drugs for Respiratory Syncytial Virus Infection Pipeline, click here @ Respiratory Syncytial Virus Infection Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Respiratory Syncytial Virus Infection Pipeline Report
• Coverage- Global
• Respiratory Syncytial Virus Infection Companies- GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others.
• Respiratory Syncytial Virus Infection Therapies- CS1001, avelumab, Isatuximab, Cemiplimab, Daratumumab, Velcade, CHOP and alemtuzumab, Busulfan, Fludarabine, YY-20394, and others
• Respiratory Syncytial Virus Infection Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Respiratory Syncytial Virus Infection Mergers and acquisitions, Respiratory Syncytial Virus Infection Licensing Activities @ Respiratory Syncytial Virus Infection Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Respiratory Syncytial Virus Infection Executive Summary
3. Respiratory Syncytial Virus (RSV): Overview
4. Respiratory Syncytial Virus Infection Pipeline Therapeutics
5. Respiratory Syncytial Virus Infection Therapeutic Assessment
6. Respiratory Syncytial Virus (RSV) - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Respiratory Syncytial Virus (RSV) Collaboration Deals
9. Late Stage Products (Phase III)
10. GSK3844766A: GlaxoSmithKline
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. EDP 938: Enanta Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. mRNA-1345: Moderna Therapeutics
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. AR-201: Aridis Pharmaceuticals
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Respiratory Syncytial Virus (RSV) Key Companies
23. Respiratory Syncytial Virus (RSV) Key Products
24. Respiratory Syncytial Virus (RSV)- Unmet Needs
25. Respiratory Syncytial Virus (RSV)- Market Drivers and Barriers
26. Respiratory Syncytial Virus (RSV)- Future Perspectives and Conclusion
27. Respiratory Syncytial Virus (RSV) Analyst Views
28. Respiratory Syncytial Virus (RSV) Key Companies
29. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Respiratory Syncytial Virus Pipeline, Clinical Trials, and Emerging Drugs (2023) | Companies- GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, and others here
News-ID: 3093352 • Views: …
More Releases from DelveInsight Business Research
Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA App …
The "Vitiligo Pipeline Insight, 2025" report by DelveInsight delivers an in-depth view of the current clinical development scenario along with the future growth trajectory of the Vitiligo Market.
As per DelveInsight's evaluation, the global Vitiligo treatment pipeline features 20+ leading companies actively engaged in developing 20+ therapeutic candidates. The analysis covers Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and developmental updates.
The Vitiligo Pipeline report offers extensive commercial and clinical…
Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Th …
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Myelodysplastic Syndrome…
Fibromyalgia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA …
According to DelveInsight, the global Fibromyalgia pipeline features more than eight key companies actively developing over ten treatment candidates. The analysis encompasses ongoing clinical trials, therapeutic mechanisms of action, routes of administration, and recent developments within the Fibromyalgia treatment landscape.
The Fibromyalgia Pipeline 2025 report provides an exhaustive evaluation of pipeline products, ranging from preclinical stages to marketed therapies. It includes comprehensive details on each drug's mechanism of action, clinical trial…
Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, F …
As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Wounds Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market.
The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment…
More Releases for Respiratory
Prevalence Of Respiratory Diseases Fuels Demand For Respiratory Disposables: Key …
The Respiratory Disposables Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Respiratory Disposables Market Size During the Forecast Period?
The respiratory disposables market has seen rapid growth in recent years. It is expected to grow from $1.01 billion in 2024 to $1.15…
Transforming the Respiratory Monitoring Devices Market in 2025: Rising Incidence …
What Is the Expected Size and Growth Rate of the Respiratory Monitoring Devices Market?
The market size for respiratory monitoring devices has seen swift expansion in the recent past. The market's growth is projected to increase from $1.67 billion in 2024 to $1.87 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. A combination of factors such as the prevalence of respiratory ailments, an aging demographic, technological innovations,…
Transforming the Respiratory Monitoring Devices Market in 2025: Rising Incidence …
What Is the Expected Size and Growth Rate of the Respiratory Monitoring Devices Market?
The market size for respiratory monitoring devices has seen swift expansion in the recent past. The market's growth is projected to increase from $1.67 billion in 2024 to $1.87 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. A combination of factors such as the prevalence of respiratory ailments, an aging demographic, technological innovations,…
Molecular Respiratory Panels Market: Enhancing Accuracy and Speed in Respiratory …
Introduction
The global molecular respiratory panels market is rapidly evolving, driven by the need for faster, more accurate diagnostics in respiratory diseases. With respiratory infections and diseases becoming increasingly prevalent worldwide, accurate detection and timely diagnosis are critical to improving patient outcomes. Molecular respiratory panels, which utilize advanced molecular techniques like PCR (Polymerase Chain Reaction) and other nucleic acid-based methods, enable the rapid identification of pathogens responsible for respiratory conditions. These…
Tackling Respiratory Challenges: Lower Respiratory Tract Therapeutics Market 202 …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Lower Respiratory Tract Therapeutics Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $48.37 billion In…
Respiratory Assist Devices Market - Breathing Uninterrupted: Innovating Respirat …
Newark, New Castle, USA - new report, titled Respiratory Assist Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Respiratory Assist Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Respiratory Assist Devices market. The report offers an overview of…
